Although BRAF inhibitor monotherapy yields response rates> 50% in BRAF V600-mutant
melanoma, only approximately 5% of patients with BRAF V600E colorectal cancer respond …

Purpose To evaluate dabrafenib, a selective BRAF inhibitor, combined with trametinib, a
selective MEK inhibitor, in patients with BRAF V600–mutant metastatic colorectal cancer …

Although recent clinical trials of BRAF inhibitor combinations have demonstrated improved
efficacy in BRAF-mutant colorectal cancer, emergence of acquired resistance limits clinical …

BRAF mutations occur in 10% to 15% of colorectal cancers and confer adverse outcome in
the metastatic setting. Although RAF inhibitors such as vemurafenib (PLX4032) have proven …

BRAF mutations occur in approximately 10% of colorectal cancers. Although RAF inhibitor
monotherapy is highly effective in BRAF-mutant melanoma, response rates in BRAF-mutant …

Oncogenic BRAF, which drives cell transformation and proliferation, has been detected in
approximately 50% of human malignant melanomas and 5% to 15% of colorectal cancers …

Introduction: BRAF driver mutations are found in up to 15% of patients with colorectal cancer
(CRC) and lead to constitutive activation of BRAF kinase and sustained RAS/RAF/MEK/ERK …

Purpose: BRAFV600E mutations are associated with poor clinical prognosis in colorectal
cancer (CRC). Although selective BRAF inhibitors are effective for treatment of melanoma …

While BRAF inhibitor combinations with EGFR and/or MEK inhibitors have improved clinical
efficacy in BRAFV600E colorectal cancer (CRC), response rates remain low and lack …

Between 8% and 12% of patients with metastatic colorectal cancer (mCRC) harbor a BRAF-
V600E mutation in their tumors, which is associated with a poor response to standard …